Akari Therapeutics received a letter from Nasdaq stating that the company's stockholders equity is below the minimum requirement for continued listing.
AI Assistant
AKARI THERAPEUTICS PLC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.